Knowledge Distillery

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding domain (RBD) targeted by most neutralizing antibodies (Abs) in…

The deployment of a vaccine that limits transmission and disease likely will be required to end the COVID-19 pandemic.

Continued uncontrolled transmission of the SARS-CoV-2 in many parts of the world is creating the conditions for significant virus evolution.

Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan, China, in December 2019, the novel coronavirus that causes…

To circumvent time-consuming clinical trials, testing whether existing drugs are effective inhibitors of SARS-CoV-2 , has led to the discovery of…

Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines.

The objective of this prospective uncontrolled cohort study was to describe the consequences at 4 months in patients hospitalized for COVID-19.

Extensive global sampling and sequencing of the pandemic virus SARS-CoV-2 have enabled researchers to monitor its spread, and to identify concerning…

A novel SARS-CoV-2 variant, VOC 202012/01 (lineage B.1.1.7), emerged in southeast England in November 2020 and is rapidly spreading toward fixation.

Substitution for aspartic acid by glycine at position 614 in the spike (S) protein of severe acute respiratory syndrome coronavirus 2 appears to…

SARS-CoV-2 infections and hospital admissions for COVID-19 increased rapidly in the South East region of England in November and December 2020,…

The efficacy of two injections of the SARS-CoV-2 spike mRNA vaccines (BNT162b2 [Pfizer] and mRNA-1273 [Moderna]) in preventing symptomatic SARS-CoV-2…